Thursday, July 13, 2017 12:22:43 AM
In looking again at VB-111, I'm more convinced than ever that it works, i.e. it has a biological effect. I'm less convinced that rGBM was/is the right initial target. I do recognize the companies mindset, an untapped, fairly large indication to gain a foothold with zero treatment options. Should they succeed, they can expand to newly diagnosed and other cancer indications. Should they fail, will they proceed with ovarian? moving to Modin? or will they retrench and move onward to the VB600 series and wait to proceed with ovarian after they finalize a NASH partnership.
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM